Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Notes Payables: 2020-2024

Historic Notes Payables for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $275,849.

  • SAB Biotherapeutics' Notes Payables fell 83.42% to $138,554 in Q1 2025 from the same period last year, while for Mar 2025 it was $138,554, marking a year-over-year decrease of 83.42%. This contributed to the annual value of $275,849 for FY2024, which is 73.75% down from last year.
  • SAB Biotherapeutics' Notes Payables amounted to $275,849 in FY2024, which was down 73.75% from $1.1 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Notes Payables peaked at $1.8 million during FY2021, and registered a low of $275,849 during FY2024.
  • For the 3-year period, SAB Biotherapeutics' Notes Payables averaged around $699,788, with its median value being $772,665 (2022).
  • Per our database at Business Quant, SAB Biotherapeutics' Notes Payables surged by 152.79% in 2021 and then tumbled by 73.75% in 2024.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Notes Payables stood at $710,768 in 2020, then skyrocketed by 152.79% to $1.8 million in 2021, then tumbled by 57.00% to $772,665 in 2022, then skyrocketed by 36.00% to $1.1 million in 2023, then tumbled by 73.75% to $275,849 in 2024.